A case of secondary cold agglutinin disease (CAD) was triggered by a rare, undetected slow-growing type of immune cell cancer in the spleen. The case study, “Cold agglutinin syndrome secondary to splenic marginal zone lymphoma: a case report,” was published in the journal Hematology, Transfusion…
News
New patient-reported outcome measures capable of adequately capturing and assessing the impact of cold agglutinin disease (CAD) symptoms are needed, a study reported. Its scientists hope that by identifying relevant patient-reported outcome measures, clinicians and others involved in managing patients’ care can gain a better understanding of the concerns…
People with cold agglutinin disease (CAD) show signs of red blood cell destruction year round, not just when the weather is cold, a new study highlights. These findings suggest that CAD patients should be closely monitored at all times, regardless of season, according to researchers. The study, “…
Suppressing the pro-inflammatory complement pathway using sutimlimab, in addition to other measures, can help prevent red blood cell destruction in patients with cold agglutinin disease (CAD) undergoing major surgery, a recent case report suggests The study, “Sutimlimab, an investigational C1s inhibitor, effectively prevents exacerbation of hemolytic anaemia…
Sutimlimab increased hemoglobin, lowered levels of red blood cell destruction markers, and eased fatigue and symptoms related to anemia in patients with cold agglutinin disease (CAD), according to a recent analysis of CADENZA. In…
A retrospective study by the National Institutes of Health (NIH) suggests that healthcare costs for those with rare diseases have been underestimated, possibly being three to five times higher than for those without rare diseases. This study provides evidence of the potential effect rare diseases may have on public health…
Cold agglutinin disease (CAD) in an elder woman worsened an underlying autoimmune condition that subsequently led to acute liver failure, a case study reports. This case highlights a need for informed understanding of CAD and its associations with other autoimmune processes, and how it can lead to early interventions…
Global Genes has partnered with the Rare Disease Diversity Coalition (RDDC) to advance health equity for rare disease patients and caregivers in underrepresented communities of color. “For rare disease patients, there are many challenges — and for people of color with a rare disease, these challenges are compounded…
The virus that causes COVID-19, SARS-CoV-2, may have triggered both warm and cold autoimmune hemolytic anemia (AIHA) in a 51-year-old man, a case study reports. The case report, “Warm and Cold Autoimmune Hemolytic Anemia in the Setting of COVID-19 Disease,” was published in the journal Cureus. AIHA comprises a…
The Rare Disease Diversity Coalition (RDDC) awarded $600,000 in grants to ease the disparities faced by rare disease patients of color. These Impact Rare Disease Solution grants will go five RDDC steering committee working groups, which aim to identify problems for rare disease communities and advocate for solutions. The five…
Recent Posts
- After a trip to the ER, I’m figuring out how to strengthen my immune system
- Study finds inherited thrombophilia screening not needed in AIHA
- For US woman, CAD exacerbates iron disorder, leading to liver damage
- Post-exertional malaise leads to a cycle of crashes and comebacks
- Enjaymo provides lasting CAD control even with fewer doses: Study
- Being vigilant during transfusions brings me a vital victory
- Rituximab helps treat CAD linked to long-term immunosuppression: Case
- With my health from CAD steadily declining, I call in the cavalry, part 3
- Rituximab effective in rare dual autoimmune blood disorder case
- Unexplained anemia in seniors may signal autoimmune disease CAD